Tumor > Neotect

Apr 2, 2002

Neotect (Tc99-m-Depreotide) (P-829)

Chemistry and pharmacology

Patient Instructions

Imaging Protocol

Indications for the exam

Complications/Side Effects

HAMA Formation (Immunogenicity)

Archeus doses first patient in phase I RPT trial

May 27, 2026

Advancing molecular imaging together

Advancing molecular imaging together

May 24, 2026

Research Money 400

Radnostix reports 27% revenue decline in Q1

May 21, 2026

Construction Pharmaceutical Manufacturing 400

Niowave breaks ground on $75M Mich. Ac-225 production facility

May 21, 2026

Archeus doses first patient in phase I RPT trial

By AuntMinnie.com staff writers

In preclinical work, Y-90 ARC-706 demonstrated tumor-selective uptake across multiple ICI-treated cancers.

May 27, 2026

Mevion to install first proton therapy system in Vietnam

By AuntMinnie.com staff writers

Mevion Medical Systems has signed an agreement to install what the firm says will be the first proton therapy system in Vietnam.

May 26, 2026

Business Handshake 400 (1)

Radnostix reports 27% revenue decline in Q1

By AuntMinnie.com staff writers

Radnostix reported a 27% decrease in the first quarter of 2026 compared to the previous year's first quarter.

May 21, 2026

Research Money 400

Niowave breaks ground on $75M Mich. Ac-225 production facility

By AuntMinnie.com staff writers

Niowave has broken ground on its Ac-225 production facility in Lansing, MI, with construction expected to be finished by 2028.

May 21, 2026

Construction Pharmaceutical Manufacturing 400

NRC to ease burden on radiopharmaceutical licensees

By AuntMinnie.com staff writers

The rule would eliminates decommissioning financial assurance (DFA) for all radionuclides with half-lives of 120 days or less.

May 19, 2026

Plus Therapeutics inks AI deal with Ephemeral Technologies

By AuntMinnie.com staff writers

Plus Therapeutics is a clinical-stage pharmaceutical company developing radiopharmaceutical therapies for CNS cancers.

May 19, 2026

SNMMI highlights new radiopharmaceutical therapy

By AuntMinnie.com staff writers

Mice bearing PDAC xenografts received lutetium-177 (Lu-177) AKIR001, a radiopharmaceutical that targets CD44v6.

May 13, 2026

Biodistribution of Lu-177 AKIR001. (A) Mice (N = 12) bearing BxPC3 tumors were injected with Lu-177 AKIR001 and dissected at 24 (N = 4), 96 (N = 4), and 168 hours (N = 4) postinjection. Error bars represent SD. (B) Representative SPECT/CT images at 96 hours postinjection. GI = gastrointestinal.

Eden Radioisotopes files NRC permit for isotope production complex

By AuntMinnie.com staff writers

The company said the facility is designed to produce up to 50% of global demand for molybdenum-99 (Mo-99).

May 6, 2026

C-Ray Therapeutics wins FDA active status for Cu-64 drug master file

By AuntMinnie.com staff writers

C-Ray Therapeutics has received active status from the FDA for its Type II Drug Master File for Cu-64 chloride for radiolabeling.

April 28, 2026

TAG1, NRG Pallas to advance Pb-212 supply for cancer therapies

By AuntMinnie.com staff writers

TAG1 and NRG Pallas aim to develop access to lead-212 (Pb-212) for cancer drug development across Europe.

April 22, 2026

A Rk Nx1 Fop15 Je H Jffj8rq D13

Ionetix raises $30M to scale radioisotope production

By AuntMinnie.com staff writers

The funding will support scaling up of radioisotope production as well as R&D efforts in nuclear energy, materials testing, and related areas.

April 21, 2026

Telix doses first patient in glioblastoma trial

By AuntMinnie.com staff writers

The patient was dosed at Austin Health in Melbourne, Australia.

April 15, 2026

Page 1 of 442